We provide high-quality treatment for all kinds of blood diseases focusing on patients. We aim to provide international-standard medicine not only for hematopoietic malignancy such as leukemia, malignant lymphoma, and multiple myeloma, but also autoimmune thrombocytopenia and aplastic anemia.
A scene of outpatient clinic
We aim to provide the best treatment for hematopoietic malignancy such as leukemia, malignant lymphoma, and multiple myeloma by introducing therapeutic protocols, the efficacy of which has been demonstrated in international clinical studies and by consulting with patients and their families. We also provide treatment for autoimmune disorders such as aplastic anemia and autoimmune thrombocytopenia following the international guidelines. In particular, for malignant lymphoma and multiple myeloma, in collaboration with the Blood Transfusion Division, we try to improve the treatment results using super-high-dose chemotherapy with autologous peripheral blood stem cell transplantation. By collaborating with test departments, we often use genetic tests and flow cytometry tests for the diagnosis of hematopoietic malignancy and the monitoring of minimal residual disease.
A scene of outpatient clinic